Severe Cholestatic Hepatitis caused by Thiazolidinediones
Troglitazone maleate (Rezulin) has been associated with severe hepatotoxicity, which led to its withdrawal from the U.S. market in March 2000. Rosiglitazone maleate (Avandia) is being marketed as a safe alternative in the treatment of type 2 diabetes mellitus. We report a case of severe thiazolidine...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| التنسيق: | article |
| منشور في: |
2002
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/4100 http://dx.doi.org/10.1023/A:1015895925374 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://link.springer.com/article/10.1023/A:1015895925374 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513462855532544 |
|---|---|
| author | Azar, Riad |
| author2 | Bonkovsky, Herbert L. Bird, Steven Szabo, Gyongyi Banner, Barbara |
| author2_role | author author author author |
| author_facet | Azar, Riad Bonkovsky, Herbert L. Bird, Steven Szabo, Gyongyi Banner, Barbara |
| author_role | author |
| dc.creator.none.fl_str_mv | Azar, Riad Bonkovsky, Herbert L. Bird, Steven Szabo, Gyongyi Banner, Barbara |
| dc.date.none.fl_str_mv | 2002 2016-06-20T07:08:33Z 2016-06-20T07:08:33Z 2016-06-20 |
| dc.identifier.none.fl_str_mv | 0163-2116 http://hdl.handle.net/10725/4100 http://dx.doi.org/10.1023/A:1015895925374 Bonkovsky, H. L., Azar, R., Bird, S., Szabo, G., & Banner, B. (2002). Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Digestive diseases and sciences, 47(7), 1632-1637. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://link.springer.com/article/10.1023/A:1015895925374 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Digestive Diseases and Sciences |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Severe Cholestatic Hepatitis caused by Thiazolidinediones risks associated with substituting Rosiglitazone for Troglitazone |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Troglitazone maleate (Rezulin) has been associated with severe hepatotoxicity, which led to its withdrawal from the U.S. market in March 2000. Rosiglitazone maleate (Avandia) is being marketed as a safe alternative in the treatment of type 2 diabetes mellitus. We report a case of severe thiazolidinedione-induced cholestatic hepatitis in a 56-year-old female patient at a university hospital who was given rosiglitazone, 8 mg/day, after she developed milder hepatotoxicity while taking troglitazone. Rosiglitazone was discontinued, and the patient was treated with prednisone, azathioprine, and ursodiol. Clinical evaluation and liver biopsy were performed and liver function tests were monitored. After being switched from troglitazone to rosiglitazone the patient developed a severe cholestatic hepatitis with marked jaundice and moderate increases in serum alkaline phosphatase and γ-glutamyltranspeptidase but only mild increases in serum aminotransferases. Discontinuation of rosiglitazone and treatment with prednisone, azathioprine, and ursodiol led to improvement, albeit with residual injury, dropout of intrahepatic bile ducts, and persisting elevations of serum alkaline phosphatase. Rosiglitazone is not always a safe alternative in patients who have had hepatotoxicity to troglitazone. It is important to monitor the serum alkaline phosphatase in addition to the serum aminotransferases in patients taking thiazolidinediones. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_d83e6853c6fbc7fd0f6eb6cd7a2ded64 |
| identifier_str_mv | 0163-2116 Bonkovsky, H. L., Azar, R., Bird, S., Szabo, G., & Banner, B. (2002). Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Digestive diseases and sciences, 47(7), 1632-1637. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/4100 |
| publishDate | 2002 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Severe Cholestatic Hepatitis caused by Thiazolidinedionesrisks associated with substituting Rosiglitazone for TroglitazoneAzar, RiadBonkovsky, Herbert L.Bird, StevenSzabo, GyongyiBanner, BarbaraTroglitazone maleate (Rezulin) has been associated with severe hepatotoxicity, which led to its withdrawal from the U.S. market in March 2000. Rosiglitazone maleate (Avandia) is being marketed as a safe alternative in the treatment of type 2 diabetes mellitus. We report a case of severe thiazolidinedione-induced cholestatic hepatitis in a 56-year-old female patient at a university hospital who was given rosiglitazone, 8 mg/day, after she developed milder hepatotoxicity while taking troglitazone. Rosiglitazone was discontinued, and the patient was treated with prednisone, azathioprine, and ursodiol. Clinical evaluation and liver biopsy were performed and liver function tests were monitored. After being switched from troglitazone to rosiglitazone the patient developed a severe cholestatic hepatitis with marked jaundice and moderate increases in serum alkaline phosphatase and γ-glutamyltranspeptidase but only mild increases in serum aminotransferases. Discontinuation of rosiglitazone and treatment with prednisone, azathioprine, and ursodiol led to improvement, albeit with residual injury, dropout of intrahepatic bile ducts, and persisting elevations of serum alkaline phosphatase. Rosiglitazone is not always a safe alternative in patients who have had hepatotoxicity to troglitazone. It is important to monitor the serum alkaline phosphatase in addition to the serum aminotransferases in patients taking thiazolidinediones.PublishedN/A2016-06-20T07:08:33Z2016-06-20T07:08:33Z20022016-06-20Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0163-2116http://hdl.handle.net/10725/4100http://dx.doi.org/10.1023/A:1015895925374Bonkovsky, H. L., Azar, R., Bird, S., Szabo, G., & Banner, B. (2002). Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Digestive diseases and sciences, 47(7), 1632-1637.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttp://link.springer.com/article/10.1023/A:1015895925374enDigestive Diseases and Sciencesinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/41002021-03-19T10:03:20Z |
| spellingShingle | Severe Cholestatic Hepatitis caused by Thiazolidinediones Azar, Riad |
| status_str | publishedVersion |
| title | Severe Cholestatic Hepatitis caused by Thiazolidinediones |
| title_full | Severe Cholestatic Hepatitis caused by Thiazolidinediones |
| title_fullStr | Severe Cholestatic Hepatitis caused by Thiazolidinediones |
| title_full_unstemmed | Severe Cholestatic Hepatitis caused by Thiazolidinediones |
| title_short | Severe Cholestatic Hepatitis caused by Thiazolidinediones |
| title_sort | Severe Cholestatic Hepatitis caused by Thiazolidinediones |
| url | http://hdl.handle.net/10725/4100 http://dx.doi.org/10.1023/A:1015895925374 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://link.springer.com/article/10.1023/A:1015895925374 |